Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DARENASDAQ:EDSANASDAQ:MNPRNASDAQ:PTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDare Bioscience$2.44+3.0%$2.89$2.35▼$4.60$21.59M1.1435,294 shs12,352 shsEDSAEdesa Biotech$2.10+3.2%$2.06$1.55▼$5.59$14.32M0.39490,165 shs25,983 shsMNPRMonopar Therapeutics$35.29+0.4%$36.30$1.72▼$54.30$215.95M1.0141,124 shs177 shsPTIProteostasis Therapeutics$11.24$0.87▼$2.72$37.57M1.161.04 million shs9,405 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDare Bioscience+1.27%-9.09%-20.79%-18.09%-33.88%EDSAEdesa Biotech+0.49%+1.49%+2.51%-12.07%-51.54%MNPRMonopar Therapeutics+4.77%+10.15%+17.16%+1.65%+876.67%PTIProteostasis Therapeutics0.00%0.00%0.00%0.00%+22.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDAREDare Bioscience2.5371 of 5 stars3.35.00.00.03.30.00.0EDSAEdesa Biotech1.7456 of 5 stars2.03.00.00.03.51.70.6MNPRMonopar Therapeutics3.0331 of 5 stars3.45.00.00.02.81.70.0PTIProteostasis TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAREDare Bioscience 2.50Moderate Buy$12.00391.80% UpsideEDSAEdesa Biotech 4.00Strong Buy$5.00138.66% UpsideMNPRMonopar Therapeutics 2.80Moderate Buy$56.5060.12% UpsidePTIProteostasis Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MNPR, DARE, PTI, and EDSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.006/23/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAREDare Bioscience$10K2,159.40N/AN/A($0.69) per share-3.54EDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/APTIProteostasis Therapeutics$5M0.00N/AN/A$1.22 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAREDare Bioscience-$4.05M-$0.17N/AN/AN/AN/AN/A-8.14%8/11/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)PTIProteostasis Therapeutics-$59.13M-$1.16N/AN/AN/AN/A-75.39%-55.04%N/ALatest MNPR, DARE, PTI, and EDSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/A5/13/2025Q1 2025DAREDare Bioscience-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAREDare BioscienceN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/APTIProteostasis TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAREDare BioscienceN/A0.560.56EDSAEdesa BiotechN/A15.7215.72MNPRMonopar TherapeuticsN/A36.9136.91PTIProteostasis TherapeuticsN/A6.696.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAREDare Bioscience6.70%EDSAEdesa Biotech5.50%MNPRMonopar Therapeutics1.83%PTIProteostasis Therapeutics16.64%Insider OwnershipCompanyInsider OwnershipDAREDare Bioscience4.00%EDSAEdesa Biotech22.60%MNPRMonopar Therapeutics20.50%PTIProteostasis Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAREDare Bioscience308.85 million8.50 millionNot OptionableEDSAEdesa Biotech207.02 million5.44 millionNot OptionableMNPRMonopar Therapeutics106.12 million4.86 millionNot OptionablePTIProteostasis Therapeutics4452.19 millionN/ANot OptionableMNPR, DARE, PTI, and EDSA HeadlinesRecent News About These CompaniesUnlocking proteostasis: A new frontier in the fight against neurodegenerative diseases like Alzheimer'sJanuary 3, 2025 | msn.comProteostasis modulates gene dosage evolution in antibiotic-resistant bacteriaOctober 31, 2024 | elifesciences.orgEDELE1 maintains muscle proteostasis to promote growth and survival in mitochondrial myopathyOctober 8, 2024 | embopress.orgEIslamabad on red alert as PTI all set to hold rally todaySeptember 9, 2024 | thenews.com.pkT‘PTI was not a party in reserved seats case’: SC judges issue dissenting opinionAugust 9, 2024 | tribune.com.pkTHarness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board ChairApril 24, 2024 | globenewswire.comNews From PTIApril 11, 2024 | health.economictimes.indiatimes.comPTI files petition in ECP for disqualification of Faryal TalpurApril 8, 2024 | radio.gov.pkRSC accepts ECP’s appeal, strips PTI of ‘bat’ symbolMarch 25, 2024 | radio.gov.pkRIndependent candidates continue to join PTI in center, PunjabMarch 12, 2024 | radio.gov.pkRPeshawar High Court lifts stay on ECP verdict nullifying PTI’s intra-party pollJanuary 30, 2024 | radio.gov.pkRExperts hail decision of ECP that PTI received funding from prohibited sourcesJanuary 13, 2024 | radio.gov.pkRFormer PTI Chairman admits recent article in Economist not written by him, AI generatedJanuary 13, 2024 | radio.gov.pkRECP declares PTI’s intra-party polls as null and voidJanuary 10, 2024 | radio.gov.pkRQureshi barred, many PTI leaders cleared to contest pollsJanuary 8, 2024 | pakistantoday.com.pkPPakistan’s ex-PM Imran and PTI party most popular in the country: PollJanuary 4, 2024 | gulftoday.aeGAs scrutiny ends, PTI faces ‘unprecedented wave’ of rejections of nominationsJanuary 1, 2024 | pakistantoday.com.pkPPTI berates ECP over irresponsible, nonsensical statement regarding judiciaryDecember 30, 2023 | pakistantoday.com.pkPPTI to play its election innings ‘without bat’ on tough pitchDecember 25, 2023 | gulftoday.aeGPTI core committee urges ECP to allocate ‘bat’ symbolDecember 17, 2023 | pakistantoday.com.pkPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Industrials Stocks Standing Out for Growth and Analyst OptimismBy Nathan Reiff | June 4, 2025View 3 Industrials Stocks Standing Out for Growth and Analyst OptimismSilver's Options Sizzle: Are Traders Betting on a Breakout?By Jeffrey Neal Johnson | June 5, 2025View Silver's Options Sizzle: Are Traders Betting on a Breakout?The Other AI Chipmaker: Why Marvell's Dip Is a BuyBy Jeffrey Neal Johnson | June 12, 2025View The Other AI Chipmaker: Why Marvell's Dip Is a BuyAT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?By Jeffrey Neal Johnson | June 5, 2025View AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?Reddit Stock Ignites: Surge in Call Options Signals Big BetBy Gabriel Osorio-Mazilli | June 24, 2025View Reddit Stock Ignites: Surge in Call Options Signals Big BetMNPR, DARE, PTI, and EDSA Company DescriptionsDare Bioscience NASDAQ:DARE$2.44 +0.07 (+2.95%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Edesa Biotech NASDAQ:EDSA$2.10 +0.07 (+3.20%) As of 09:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Monopar Therapeutics NASDAQ:MNPR$35.29 +0.13 (+0.36%) As of 09:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Proteostasis Therapeutics NASDAQ:PTIProteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
